Table 3.

Kidney function measurement before and during dopamine infusion (predopamine and dopamine, respectively) according to age group

VariablesAge, yr
18–2930–3940–4950–59≥60
PredopamineDopaminePredopamineDopaminePredopamineDopaminePredopamineDopaminePredopamineDopamine
ADPKD
N1726415016
 Measured GFR, ml/min per 1.73 m2103±21114±25a90±1893±19b62±2566±28a53±2154±2338±1938±20
 Effective kidney plasma flow, ml/min per 1.73 m2317±78363±96a260±44284±53a192±76220±95a169±66187±80a123±49131±57b
 Filtration fraction, %33.5±4.432.5±4.6b34.5±4.133.1±4.3b32.2±4.230.7±4.1a31.1±3.829.3±4.2a29.6±4.128.6±4.7b
Healthy controls
N1726415016
 Measured GFR, ml/min per 1.73 m2111±9117±8b109±10120±13a104±15116±18a97±14105±16a89±1897±16a
 Effective kidney plasma flow, ml/min per 1.73 m2347±42387±57a346±58403±72a326±51379±69a299±46343±59a282±57319±56a
 Filtration fraction, %32.7±4.931.1±5.1b32.2±4.230.0±4.3b32.2±3.631.1±4.1b32.8±3.831.2±3.8a31.9±3.830.9±3.7b
  • Variables are presented as mean±SD. Differences were tested with a paired t test. ADPKD, autosomal dominant polycystic kidney disease.

  • a P<0.001 between predopamine and dopamine.

  • b P<0.05 between predopamine and dopamine.